1. Search Result
Search Result
Targets Recommended: CRISPR/Cas9 Arp2/3 Complex
Results for "

1616428-23-9

" in MCE Product Catalog:
Cat. No. Product Name Target Research Areas
  • HY-139535
    Luxeptinib

    CG-806

    FLT3 Btk Cancer
    Luxeptinib (CG-806) is an orally active, reversible, first-in-class, non-covalent and potent pan-FLT3/pan-BTK inhibitor. Luxeptinib induces cell cycle arrest, apoptosis or autophagy in acute myeloid leukemia cells.